Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20011906 | 0.80 | USP2 (0.42) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL15858034 | 0.77 | USP2 (0.42) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL20400359 | 0.76 | MMP1 (0.45) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL24876558 | 0.74 | NR1H2 (0.41) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL17897238 | 0.74 | USP2 (0.40) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL12571979 | 0.74 | USP2 (0.40) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL25768050 | 0.73 | NR1H2 (0.49) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL14717644 | 0.73 | NR1H2 (0.49) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL14717643 | 0.73 | NR1H2 (0.49) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 | |
| SCHEMBL30663101 | 0.73 | NR1H2 (0.38) | USP2SMN1; SMN2NR1H2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | F13A1 361/4885TGM2 3156/4885USP2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.